-
Budget Impact Analysis of Revumenib for the Treatment of Relapsed or Refractory Acute Leukemias with a KMT2A Translocation in the United States
-
Budget Impact Analysis of Revumenib for the Treatment of Relapsed or Refractory (R/R) NPM1-Mutated Acute Myeloid Leukemia (AML) in the United States
-
AXALAP: Phase Ib study of AXAtilimab in Combination with OLAParib in BRCA1/2 and PALB2-associated metastatic HER2-negative breast cancer
-
The Effects of Prior Lines of Therapy on Clinical Outcomes for Patients with Chronic Graft-Versus-Host Disease Receiving Axatilimab: A Post Hoc Analysis of AGAVE-201
-
Dynamics of Overall and Organ-Specific Responses to Axatilimab in Chronic Graft-Versus-Host Disease: Analysis From the AGAVE-201 Study
-
Correlations of Clinician-Reported Responses With Other Response Measures in Patients With Chronic Graft-Versus-Host Disease: An Analysis From the AGAVE-201 Trial
-
Trial in Progress: A Randomized, Open-Label, Phase 3 Study of Axatilimab Versus Best Available Therapy in Patients With Chronic Graft-Versus-Host Disease After ≥2 Prior Lines of Systemic Therapy
-
Inhibition of CSF1R-CSF1 Axis with Axatilimab Effectively Targets Leukemia Stem Cells and Monocytes in BH3 Mimetics-Resistant AML
-
Axatilimab in combination with ruxolitinib in patients with newly diagnosed chronic graft-versus-host disease: interim safety analysis of a phase 2, randomized study
-
Phase 1 Study of Revumenib in Combination With Intensive Chemotherapy (IC) in Patients (Pts) With Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Harboring Genetic Alterations in KMT2A, NPM1, or NUP98: SNDX-5613-0708
-
Preliminary Results of a Phase 1 Study of the Safety and Tolerability of the Combination of Revumenib (REV) With Gilteritinib (GILT) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
-
Patients With Relapsed or Refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Updated Results from the Phase 2 AUGMENT-101 Study
-
Updated Results and Longer Follow-Up From the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia
-
Revumenib Activity in Patients with NUP98r Acute Leukemia: Results from the AUGMENT-101 Phase 1 Study
-
Revumenib in Combination with Intensive Induction and Consolidation for Newly Diagnosed Patients with NPM1-mutated or KMT2A-rearranged Acute Myeloid Leukemia: Preliminary Results from the Phase 1b ETCTN 10596 study
-
Early Real-World Experience with Revumenib Outside of a Clinical Trial Setting: A Single Center Retrospective Review of Efficacy and Tolerability
-
Post-transplant maintenance with revumenib in children with HOX-driven AML
-
Revumenib for Patients with Relapsed or Refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Outcomes by Prior Treatment in the Phase 2 AUGMENT-101 Study
-
Phase 1/2 study of the all-oral combination of revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) in relapsed/refractory AML
-
Pharmacokinetic assessment of revumenib in patients with relapsed/refractory acute leukemias harboring a KMT2A rearrangement or NPM1 mutation: Impact of food and concomitant medications
-
Revumenib in the real world: interim findings from the ROAR study in relapsed/refractory acute leukemia
-
A phase 1/2 study of the menin inhibitor revumenib with the CELMod mezigdomide in relapsed/refractory KMT2A-rearanged, NPM1-mutant, and NUP98-rearranged acute leukemias
-
Efficacy of revumenib in acute myeloid leukemia harboring NPM1-mutated co-mutations: post hoc analysis of AUGMENT-101
-
Revumenib therapy post hematopoietic stem cell transplant for patients with relapsed/refractory KMT2Ar, NPM1m, and NUP98r acute myeloid leukemia: post hoc analysis of outcomes from AUGMENT-101
-
Long-term follow-up of pediatric/young adult patients with relapsed/refractory KMT2Ar acute leukemia treated with revumenib in AUGMENT-101
-
Revumenib + intensive chemotherapy for newly diagnosed acute myeloid leukemia harboring genetic alterations in KMT2A, NPM1, or NUP98: updated phase 1 results from SNDX-5613-0708
-
Revumenib as maintenance for AML following allogeneic stem cell transplantation
-
Clinical activity of revumenib in patients with relapsed/refractory NUP98-rearranged acute leukemias
-
A phase 3 study of revumenib plus venetoclax/azacitidine in adults with newly diagnosed NPM1-mutated or KMT2A-rearranged acute myeloid leukemia ineligible for intensive chemotherapy (EVOLVE-2/HO177/AMLSG35-24/ACT-HOV-AML-002): Trial in progress.
-
A phase 3 study of revumenib in combination with intensive chemotherapy in patients with newly diagnosed NPM1-mutated acute myeloid leukemia (REVEAL-ND NPM1): Trial in progress